Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 1
2008 2
2009 1
2010 9
2011 10
2012 8
2013 19
2014 22
2015 25
2016 19
2017 8
2018 20
2019 12
2020 39
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

177 results
Results by year
Filters applied: . Clear all
Page 1
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
FINDINGS: We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 340%, 9 …
FINDINGS: We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symp …
Siltuximab.
[No authors listed] [No authors listed] 2016 Apr 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31644237 Free Books & Documents. Review.
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltuximab commonly causes mild serum aminotransferase elevations which are usually short lived and asymptomatic, but it has not been linked
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltu
Siltuximab.
[No authors listed] [No authors listed] 2020 Dec 21. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999789 Free Books & Documents. Review.
No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein molecule with a molecular weight of about 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is proba …
No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein mole …
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. van Rhee F, et al. Lancet Haematol. 2020 Mar;7(3):e209-e217. doi: 10.1016/S2352-3026(19)30257-1. Epub 2020 Feb 3. Lancet Haematol. 2020. PMID: 32027862 Free article. Clinical Trial.
This extension study enrolled 60 patients who completed the previous trials without disease progression on siltuximab. Patients received siltuximab infusions of 11 mg/kg every 3 weeks (which could be extended to 6 weeks) for up to 6 years. ...Only two serious advers …
This extension study enrolled 60 patients who completed the previous trials without disease progression on siltuximab. Patients recei …
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
Palanques-Pastor T, López-Briz E, Poveda Andrés JL. Palanques-Pastor T, et al. Eur J Hosp Pharm. 2020 Sep;27(5):297-298. doi: 10.1136/ejhpharm-2020-002322. Epub 2020 Jun 4. Eur J Hosp Pharm. 2020. PMID: 32499314 Free PMC article. Review.
Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strateg …
Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infe …
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F. Ferrario A, et al. Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Expert Opin Investig Drugs. 2017. PMID: 28140696 Review.
Areas covered: This review discusses available data related to the role of IL-6 as a therapeutic target, the characteristics of Siltuximab in term pharmacokinetics and pharmacodynamics properties and a detailed analysis of the studies involving haematological malignancies …
Areas covered: This review discusses available data related to the role of IL-6 as a therapeutic target, the characteristics of Siltuxima
Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J, Aird G, Ahmed A, Silberstein PT. Sitenga J, et al. Patient Relat Outcome Meas. 2018 Jan 12;9:35-41. doi: 10.2147/PROM.S140011. eCollection 2018. Patient Relat Outcome Meas. 2018. PMID: 29391839 Free PMC article. Review.
Clinical trials with siltuximab have shown early clinical promise for patients with MCD for many years, leading to recent US Food and Drug Administration approval as a novel agent for the treatment of MCD. Here, a systematic review was conducted to include 171 cases of MCD …
Clinical trials with siltuximab have shown early clinical promise for patients with MCD for many years, leading to recent US Food and …
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF. Chen F, et al. J Immunol Methods. 2016 Jul;434:1-8. doi: 10.1016/j.jim.2016.03.005. Epub 2016 Apr 3. J Immunol Methods. 2016. PMID: 27049586 Free PMC article.
Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively treated with cytokine blockade using the antibodies, Siltuximab or Tocilizumab respectively targeting IL-6 or the IL-6 receptor. ...Our results indicate good agreem …
Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively treated with cytokine blockade …
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA. Lyseng-Williamson KA. BioDrugs. 2015 Dec;29(6):399-406. doi: 10.1007/s40259-015-0142-5. BioDrugs. 2015. PMID: 26394632 Review.
In clinical trials in patients with iMCD, siltuximab reduced levels of C-reactive protein (a biomarker for IL-6), and provided clinical responses. ...In the absence of a cure, siltuximab represents a significant achievement in the management of this difficult-to-tre …
In clinical trials in patients with iMCD, siltuximab reduced levels of C-reactive protein (a biomarker for IL-6), and provided clinic …
Clinical development of siltuximab.
Davis CC, Shah KS, Lechowicz MJ. Davis CC, et al. Curr Oncol Rep. 2015 Jul;17(7):29. doi: 10.1007/s11912-015-0453-1. Curr Oncol Rep. 2015. PMID: 25986720 Review.
Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical development and pharmaceutical approval of siltuximab....
Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical
177 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page